Misplaced Pages

Duearity

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Swedish medical products company

Duearity AB
FormerlyCochlearity
Company typePublic (Aktiebolag)
Traded asNasdaq Stockholm First North: DEAR
ISINSE0015949482
IndustryMedical equipment  ·
Tinnitus treatment
DefunctSeptember 10, 2024 (2024-09-10)
HeadquartersMalmö, Sweden
Key people
ProductsTinearity G1
Tinearity AI
Websitewww.duearity.com
Footnotes / references

Duearity was a Swedish medical technology company based in Malmö. The company specialised in hardware and software for tinnitus treatment. From May 2021 to September 2024, Duearity was publicly traded on the Nasdaq First North stock exchange.

Origins

Peter Arndt, one of Duearity's founders, was undergoing tinnitus retraining therapy (TRT) and noticed the treatment to be effective, but incompatible with daily life. Tinnitus retraining therapy is based on cognitive behavioral therapy and requires white noise to be played uninterrupted for 6-8 hours per day for 6-24 months. Wearing headphones for prolonged and uninterrupted period of time was interfering with work during daytime and with sleep during nighttime.

The founders set out to find a solution that did not require headphones and did not occupy the ear canals. In 2020, a proof of concept was successfully completed and the company applied for a patent.

IPO

On 11 May 2021, the company's shares debuted on Nasdaq First North under ticker symbol DEAR. The company was previously called Cochlearity, but the name was changed pre-IPO in order to avoid mixup with another medtech company.

75,3% of the IPO shares were subscribed before the IPO offer was made public. Duearity’s IPO was oversubscribed by 9 times.

Products and market

Duearity is focusing its products on white noise and tinnitus retraining therapy, which has been shown to be effective in a variety of research studies.

Since 2020, Duearity has been developing the world's smallest and most flexible tinnitus aid that emits white noise through bone conduction technology. It is a patented medtech CE class IIa product with FDA 510(k) clearance in the U.S. It is a non-invasive device that attaches behind the ears and keeps the ear canals free.

Duearity is also developing a software for analysing tinnitus and managing its symptoms. The company observes strong interest from researchers, audiologists and otorhinolaryngologists.

References

  1. "Duearity AB (publ) i konkurs". Duearity (in Swedish). 23 September 2024. Archived from the original on 27 September 2024. Retrieved 27 September 2024.
  2. "First North-listade Duearity handelsstoppad – ska ansöka om konkurs". Dagens industri (in Swedish). 6 September 2024. Archived from the original on 11 September 2024. Retrieved 27 September 2024.
  3. ^ Annual Report 2021: arsredovisning-2021-duearity-ab-signerad.pdf Archived 10 December 2022 at the Wayback Machine, accessdate: 6 december 2022
  4. MedTech Magazine: Cochlearity blir Duearity inför börsnotering - MedTech Magazine Archived 15 December 2022 at the Wayback Machine, accessdate: 6 december 2022
  5. Nasdaq: DEAR, Duearity, (SE0015949482) - Nasdaq Archived 15 December 2022 at the Wayback Machine, accessdate: 6 december 2022
  6. Bolagsverket: Sök företagsinformation Företag - Sök företagsinformation, accessdate: 6 december 2022
  7. Skatteverket: Duearity AB | Skatteverket Archived 15 December 2022 at the Wayback Machine, accessdate: 6 december 2022
  8. The Wall Street Journal: Duearity DEAR.SE | Duearity AB Financial Statements - WSJ Archived 15 December 2022 at the Wayback Machine, accessdate: 6 december 2022
  9. "Duearity Aktie" (in Swedish). Dagens industri. 15 December 2022. Retrieved 15 December 2022.
  10. "Delisting of Duearity AB (publ) from Nasdaq First North Growth Market". Nasdaq. 10 September 2024. Archived from the original on 27 September 2024. Retrieved 27 September 2024.
  11. Göransson, Anders (11 September 2024). "Tidigare börsraketen i konkurs – "Fortsatt drift inte möjlig"". Medtech Magazine (in Swedish). Archived from the original on 27 September 2024. Retrieved 27 September 2024.
  12. Gisborn, Linus (13 September 2024). "VD:ns hårda ord efter konkursen: "Förväxta bebisinvesterare"". Affärsvärlden (in Swedish). Archived from the original on 27 September 2024. Retrieved 27 September 2024.
  13. "Duearity". Skatteverket (in Swedish). 11 May 2021. Archived from the original on 27 September 2024. Retrieved 27 September 2024.
  14. Nasdaq: Listing of Duearity AB (publ), on Nasdaq First North Growth Market (203/21) | Nasdaq, accessdate: 6 december 2022
  15. Hörselbolaget Duearity till First North: Hörselbolaget Duearity till First North Archived 1 December 2022 at the Wayback Machine, accessdate: 6 december 2022
  16. Affärsvärlden: Duearity - IPO | Affärsvärlden Archived 25 January 2022 at the Wayback Machine, accessdate: 6 december 2022
  17. Digital Health Technology News: Swedish MedTech startup starts pre-sale of unique product for tinnitus treatment - Digital Health Technology News Archived 9 February 2022 at the Wayback Machine, accessdate: 6 december 2022
  18. MedTech Magazine: Malmöbolag lanserar produkt för egenbehandling av tinnitus - MedTech Magazine Archived 15 December 2022 at the Wayback Machine, accessdate: 6 december 2022
  19. "Duearity AB:s halvårsrapport för perioden 1 januari till 30 juni 2021". Nasdaq News (in Swedish). 25 August 2021. Retrieved 15 December 2022.
  20. ^ "Duearity 2022 Q3" (PDF). MFN (in Swedish). Retrieved 15 December 2022.
  21. MedTech Magazine: Cochlearity blir Duearity inför börsnotering - MedTech Magazine Archived 15 December 2022 at the Wayback Machine, accessdate: 6 december 2022
  22. "IPO Guide: Duearity". Affärsvärlden. Retrieved 15 December 2022.
  23. Liedholm, Kim (20 April 2021). "Duearity vill hjälpa personer med tinnitusbesvär". BioStock (in Swedish). Retrieved 15 December 2022.
  24. "Duearitys emission kraftigt övertecknad". Dagens PS (in Swedish). 30 April 2021. Retrieved 15 December 2022.
  25. Grewal R, Spielmann PM, Jones SE, Hussain SS (December 2014). "Clinical efficacy of tinnitus retraining therapy and cognitive behavioural therapy in the treatment of subjective tinnitus: a systematic review". J Laryngol Otol. 128 (12): 1028–33. doi:10.1017/S0022215114002849. PMID 25417546. S2CID 42092743.
  26. Bauer CA, Berry JL, Brozoski TJ (August 2017). "The effect of tinnitus retraining therapy on chronic tinnitus: A controlled trial". Laryngoscope Investig Otolaryngol. 2 (4): 166–177. doi:10.1002/lio2.76. PMC 5562945. PMID 28894836.
  27. Herraiz C, Hernandez FJ, Toledano A, Aparicio JM (2007). "Tinnitus retraining therapy: prognosis factors". Am J Otolaryngol. 28 (4): 225–9. doi:10.1016/j.amjoto.2006.09.004. PMID 17606035.
  28. Han M, Yang X, Lv J (2021). "Efficacy of tinnitus retraining therapy in the treatment of tinnitus: A meta-analysis and systematic review". Am J Otolaryngol. 42 (6): 103151. doi:10.1016/j.amjoto.2021.103151. PMID 34303210.
  29. BioStock: Duearity vill hjälpa personer med tinnitusbesvär - BioStock Archived 15 December 2022 at the Wayback Machine, accessdate: 6 december 2022
  30. Duearity ska noteras på Nasdaq First North den 11 maj: Duearity ska noteras på Nasdaq First North den 11 maj Archived 9 May 2021 at the Wayback Machine, accessdate: 6 december 2022
  31. Svensk Patentdatabas, Träfflista: Svensk Patentdatabas, Träfflista Archived 15 December 2022 at the Wayback Machine, accessdate: 6 december 2022
  32. PRV avser att godkänna Duearitys patentansökan: PRV avser att godkänna Duearitys patentansökan Archived 15 December 2022 at the Wayback Machine, accessdate: 6 december 2022
  33. "510(k) Notification". Food and Drug Administration – accessdata.fda.gov. 1 November 2002. Archived from the original on 24 May 2024. Retrieved 24 May 2024.
  34. "510(k) Summary" (PDF). accessdata.fda.gov. 24 May 2024. Archived from the original (PDF) on 24 May 2024. Retrieved 24 May 2024.
  35. "Swedish Patent Database, Results list". Swedish Patent Database. 27 July 2020. Retrieved 14 December 2022.

External links

Further reading

See also

Portals: Categories: